Pharmacokinetics and pharmacodynamics of A77 1726 and leflunomide in domestic cats

M. L. Mehl, Lisa A Tell, A. E. Kyles, Yi-Je Chen, A. Craigmill, C. R. Gregory

Research output: Contribution to journalArticle

Abstract

The pharmacokinetics and pharmacodynamics of A77 1726 and leflunomide after intravenous (i.v.) and oral (p.o.) administration were evaluated in adult cats. Three treatments were administered: a single i.v. dose of A77 1726 (4mg/kg), a single oral dose of leflunomide (4mg/kg), and multiple oral doses of leflunomide (2mg/kg). Mean pharmacokinetic parameter values after a single i.v. dose of A77 1726 were distribution (A) and elimination (B) intercepts (15.2μg/mL and 34.5μg/mL, respectively), distribution and elimination half-lives (1.5 and 71.8h, respectively), area under the curve (AUC 0→∞; 3723μg*h/mL), mean residence time (MRT; 93h), clearance (Cl obs; 1.1mL/kg/h), and volume of distribution at steady state (Vd ss; 97mL/kg). Mean pharmacokinetic parameter values after a single oral dose of leflunomide were absorption and elimination rate constants (0.3 1/h and 0.01 1/h, respectively), absorption and elimination half-lives (2.3 and 59.1h, respectively), AUC 0→∞ (3966μg*h/mL), and maximum observed plasma concentration (C max; 38μg/mL). The bioavailability after a single oral dose of leflunomide was 100%. The mean±SD A77 1726 concentration that inhibited 50% lymphocytes (EC 50) was 16±13.5μg/mL. The mean±SD maximum A77 1726 concentration (EC max) was 61.0±23.9μg/mL.

Original languageEnglish (US)
Pages (from-to)139-146
Number of pages8
JournalJournal of Veterinary Pharmacology and Therapeutics
Volume35
Issue number2
DOIs
StatePublished - Apr 2012

Fingerprint

leflunomide
A 771726
pharmacology
pharmacokinetics
Cats
Pharmacokinetics
mouth
cats
Area Under Curve
dosage
half life
Biological Availability
Oral Administration
bioavailability
Lymphocytes
lymphocytes

ASJC Scopus subject areas

  • Pharmacology
  • veterinary(all)

Cite this

Pharmacokinetics and pharmacodynamics of A77 1726 and leflunomide in domestic cats. / Mehl, M. L.; Tell, Lisa A; Kyles, A. E.; Chen, Yi-Je; Craigmill, A.; Gregory, C. R.

In: Journal of Veterinary Pharmacology and Therapeutics, Vol. 35, No. 2, 04.2012, p. 139-146.

Research output: Contribution to journalArticle

@article{f0e1626f5bb145278553ab7d1ba9f401,
title = "Pharmacokinetics and pharmacodynamics of A77 1726 and leflunomide in domestic cats",
abstract = "The pharmacokinetics and pharmacodynamics of A77 1726 and leflunomide after intravenous (i.v.) and oral (p.o.) administration were evaluated in adult cats. Three treatments were administered: a single i.v. dose of A77 1726 (4mg/kg), a single oral dose of leflunomide (4mg/kg), and multiple oral doses of leflunomide (2mg/kg). Mean pharmacokinetic parameter values after a single i.v. dose of A77 1726 were distribution (A) and elimination (B) intercepts (15.2μg/mL and 34.5μg/mL, respectively), distribution and elimination half-lives (1.5 and 71.8h, respectively), area under the curve (AUC 0→∞; 3723μg*h/mL), mean residence time (MRT; 93h), clearance (Cl obs; 1.1mL/kg/h), and volume of distribution at steady state (Vd ss; 97mL/kg). Mean pharmacokinetic parameter values after a single oral dose of leflunomide were absorption and elimination rate constants (0.3 1/h and 0.01 1/h, respectively), absorption and elimination half-lives (2.3 and 59.1h, respectively), AUC 0→∞ (3966μg*h/mL), and maximum observed plasma concentration (C max; 38μg/mL). The bioavailability after a single oral dose of leflunomide was 100{\%}. The mean±SD A77 1726 concentration that inhibited 50{\%} lymphocytes (EC 50) was 16±13.5μg/mL. The mean±SD maximum A77 1726 concentration (EC max) was 61.0±23.9μg/mL.",
author = "Mehl, {M. L.} and Tell, {Lisa A} and Kyles, {A. E.} and Yi-Je Chen and A. Craigmill and Gregory, {C. R.}",
year = "2012",
month = "4",
doi = "10.1111/j.1365-2885.2011.01306.x",
language = "English (US)",
volume = "35",
pages = "139--146",
journal = "Journal of Veterinary Pharmacology and Therapeutics",
issn = "0140-7783",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Pharmacokinetics and pharmacodynamics of A77 1726 and leflunomide in domestic cats

AU - Mehl, M. L.

AU - Tell, Lisa A

AU - Kyles, A. E.

AU - Chen, Yi-Je

AU - Craigmill, A.

AU - Gregory, C. R.

PY - 2012/4

Y1 - 2012/4

N2 - The pharmacokinetics and pharmacodynamics of A77 1726 and leflunomide after intravenous (i.v.) and oral (p.o.) administration were evaluated in adult cats. Three treatments were administered: a single i.v. dose of A77 1726 (4mg/kg), a single oral dose of leflunomide (4mg/kg), and multiple oral doses of leflunomide (2mg/kg). Mean pharmacokinetic parameter values after a single i.v. dose of A77 1726 were distribution (A) and elimination (B) intercepts (15.2μg/mL and 34.5μg/mL, respectively), distribution and elimination half-lives (1.5 and 71.8h, respectively), area under the curve (AUC 0→∞; 3723μg*h/mL), mean residence time (MRT; 93h), clearance (Cl obs; 1.1mL/kg/h), and volume of distribution at steady state (Vd ss; 97mL/kg). Mean pharmacokinetic parameter values after a single oral dose of leflunomide were absorption and elimination rate constants (0.3 1/h and 0.01 1/h, respectively), absorption and elimination half-lives (2.3 and 59.1h, respectively), AUC 0→∞ (3966μg*h/mL), and maximum observed plasma concentration (C max; 38μg/mL). The bioavailability after a single oral dose of leflunomide was 100%. The mean±SD A77 1726 concentration that inhibited 50% lymphocytes (EC 50) was 16±13.5μg/mL. The mean±SD maximum A77 1726 concentration (EC max) was 61.0±23.9μg/mL.

AB - The pharmacokinetics and pharmacodynamics of A77 1726 and leflunomide after intravenous (i.v.) and oral (p.o.) administration were evaluated in adult cats. Three treatments were administered: a single i.v. dose of A77 1726 (4mg/kg), a single oral dose of leflunomide (4mg/kg), and multiple oral doses of leflunomide (2mg/kg). Mean pharmacokinetic parameter values after a single i.v. dose of A77 1726 were distribution (A) and elimination (B) intercepts (15.2μg/mL and 34.5μg/mL, respectively), distribution and elimination half-lives (1.5 and 71.8h, respectively), area under the curve (AUC 0→∞; 3723μg*h/mL), mean residence time (MRT; 93h), clearance (Cl obs; 1.1mL/kg/h), and volume of distribution at steady state (Vd ss; 97mL/kg). Mean pharmacokinetic parameter values after a single oral dose of leflunomide were absorption and elimination rate constants (0.3 1/h and 0.01 1/h, respectively), absorption and elimination half-lives (2.3 and 59.1h, respectively), AUC 0→∞ (3966μg*h/mL), and maximum observed plasma concentration (C max; 38μg/mL). The bioavailability after a single oral dose of leflunomide was 100%. The mean±SD A77 1726 concentration that inhibited 50% lymphocytes (EC 50) was 16±13.5μg/mL. The mean±SD maximum A77 1726 concentration (EC max) was 61.0±23.9μg/mL.

UR - http://www.scopus.com/inward/record.url?scp=84857996863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857996863&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2885.2011.01306.x

DO - 10.1111/j.1365-2885.2011.01306.x

M3 - Article

VL - 35

SP - 139

EP - 146

JO - Journal of Veterinary Pharmacology and Therapeutics

JF - Journal of Veterinary Pharmacology and Therapeutics

SN - 0140-7783

IS - 2

ER -